Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.63 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 2/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6582287 | 0.95 | CYP4F2 (0.66) | CYP4F2CYP4A11NPSR1ITGB1ITGA4 | |
| SCHEMBL6628381 | 0.92 | CYP4F2 (0.61) | CYP4F2CYP4A11NPSR1ITGB1ITGA4 | |
| SCHEMBL6631820 | 0.89 | CYP4F2 (0.57) | CYP4F2CYP4A11NPSR1ITGB1ITGA4 | |
| SCHEMBL8281782 | 0.88 | CYP4F2 (0.56) | CYP4F2CYP4A11NPSR1ITGB1ITGA4 | |
| SCHEMBL11088776 | 0.80 | CYP4F2 (0.69) | CYP4F2CYP4A11NPSR1ITGB1ITGA4 | |
| SCHEMBL6582646 | 0.80 | KMT2A (0.45) | CYP4F2CYP4A11ALDH1A1MEN1KMT2A | |
| SCHEMBL22070954 | 0.79 | CYP4F2 (0.96) | CYP4F2CYP4A11NPSR1ITGB1ITGA4 | |
| SCHEMBL6628282 | 0.79 | CYP4F2 (0.67) | CYP4F2CYP4A11NPSR1ALDH1A1MEN1 | |
| SCHEMBL3150942 | 0.79 | CYP4F2 (0.72) | CYP4F2CYP4A11NPSR1MEN1KMT2A | |
| SCHEMBL15572899 | 0.78 | CYP4F2 (0.51) | CYP4F2CYP4A11NPSR1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040210051-A1 | N-alkanoylphenylalanine derivatives | CHEN LI (US) | 2004-10-21 | — | — | US | disclosed |
| US-6806365-B2 | ACTIVITY AS INHIBITORS OF BINDING BETWEEN VCAM-1 AND CELLS EXPRESSING VLA-4. SUCH COMPOUNDS ARE USEFUL FOR TREATING DISEASES WHOSE SYMPTOMS AND/OR DAMAGE ARE RELATED TO THE BINDING OF VCAM-1 TO CELLS EXPRESSING VLA-4. | HOFFMANN-LA ROCHER INC. | 2004-10-19 | — | — | US | disclosed |
| EP-1005446-B1 | N-AROYLPHENYLALANINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-02-25 | — | — | EP | disclosed |
| US-20030109459-A1 | N-alkanoylphenylalamine derivatives | CHEN LI (US) | 2003-06-12 | — | — | US | disclosed |
| US-6455550-B1 | INHIBITORS OF BINDING BETWEEN VASCULAR CELL ADHESION MOLECULES AND CELLS EXPRESSING VLA-4 INTEGRIN; ANTIINFLAMMATORY AGENTS | HOFFMANN-LA ROCHE INC. | 2002-09-24 | — | — | US | disclosed |
| EP-1005446-A1 | N-AROYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999010313-A1 | N-AROYLPHENYLALANINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109459-A1 | N-alkanoylphenylalamine derivatives | VCAM1, ICAM1, SELL | CYP4F2 2193/4885CYP4A11 1183/4885NPSR1 1942/4885 |
| US-20040210051-A1 | N-alkanoylphenylalanine derivatives | VCAM1, ICAM1, CD59 | CYP4F2 1986/4885CYP4A11 1935/4885NPSR1 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.